ArticleCardio-oncology (London, England)2020

Clinical impact of interruption in adjuvant Trastuzumab therapy in patients with operable HER-2 positive breast cancer.

Sagar Sardesai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.